Moderna is trading at $216.65 (-11.86%) as investors reassess its valuation after a sharp rally tied to positive Phase 3 melanoma-vaccine news.
- Full data for the Merck-partnered vaccine are expected at the ESMO conference; its broader potential remains uncertain.
- Risk-off trading may add pressure as renewed Middle East tensions lifted oil prices and weighed on equities.